Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

17.98 +0.72 (+4.20%)
Streaming Delayed Price Updated: 11:05 AM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Shares of Roivant Sciences Were Down Tuesday
After a run-up last week prompted by positive clinical trial results, the stock has given back its recent gains. 
Via The Motley Fool
Analyst Expectations for Roivant Sciences's Future
 
Via Benzinga
Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years
 
Via Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
From Roivant Sciences
Via GlobeNewswire
Expert Ratings for Roivant Sciences
 
Via Benzinga
Roivant Sciences's Earnings Outlook
 
Via Benzinga
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
From Roivant Sciences
Via GlobeNewswire
Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
PVTX-321 and PVTX-405 Achieve Development Candidate Nomination 
From Roivant Sciences
Via GlobeNewswire
Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement
From Roivant Sciences
Via GlobeNewswire
Where Roivant Sciences Stands With Analysts
 
Via Benzinga
Roivant Sciences Announces Change to its Board of Directors
From Roivant Sciences
Via GlobeNewswire
Immunovant Could Potentially Be An M&A Target, Writes Analyst
 
Via Benzinga
Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data
Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.  
Via Benzinga
Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Earnings Scheduled For February 13, 2023
Companies Reporting Before The Bell • EuroDry (NASDAQ:EDRY) is expected to report quarterly earnings at $2.68 per share on revenue of $21.20 million. 
Via Benzinga
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Announces Proposed Public Offering of Common Shares
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023
From Roivant Sciences
Via GlobeNewswire
Roivant Touts Encouraging Early Data From Ulcerative Colitis Candidate
 
Via Benzinga
Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker
From Roivant Sciences
Via GlobeNewswire
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5.  Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on... 
Via Benzinga
Why Roivant Sciences' Shares Are Up Thursday
The company is collaborating with Pfizer to create a portfolio company to develop an encouraging drug to treat ulcerative colitis. 
Via The Motley Fool
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
From Roivant Sciences
Via GlobeNewswire
Pinterest To $23? Plus This Analyst Slashes PT On Neoleukin Therapeutics By More Than 90%
Rosenblatt raised the price target on Pinterest, Inc. (NYSE: PINS) from $21 to $23. Rosenblatt analyst Barton Crockett maintained a Neutral rating on the stock. Pinterest shares rose 2% to $24.91 in... 
Via Benzinga
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
  Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday. 
Via Benzinga
Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC
From Roivant Sciences
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares rose 49.1% to $3.22 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. 
Via Benzinga
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.